首页> 外文期刊>The Tohoku Journal of Experimental Medicine >Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma.
【24h】

Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma.

机译:Ets-1原癌基因可能预示着肺腺癌预后不良。

获取原文
获取原文并翻译 | 示例
           

摘要

The proto-oncogene Ets-1 is a transcription factor that is known to regulate certain matrix metalloproteinases and plasminogen activator, which have been associated with malignant behaviors in solid carcinomas. We hypothesized that Ets-1 expression is also associated with tumor progression and a worse prognosis in lung carcinoma patients. To clarify the role of the Ets-1 proto-oncogene, the expression of Ets-1 in non-small cell lung carcinomas using 156 paraffin-embedded specimens was determined in surgically resected tissue samples. Immunohistochemical staining showed Ets-1 expression in 82 cases of 156 carcinomas (53%): 36 of 52 (69%) squamous cell carcinomas, 41 of 96 (43%) adenocarcinomas, and 5 of 8 (63%) other carcinomas. In adenocarcinomas, a higher proportion of acinar type expressed Ets-1 compared to papillary or alveolar type (p < 0.05). The proportion of adenocarcinoma that expressed Ets-1 increased with poorer histologic differentiation of the adenocarcinoma (p < 0.05). Ets-1 positive adenocarcinomas had a larger mean size than Ets-1 negative adenocarcinomas (p < 0.01). In adenocarcinoma patients, expression of Ets-1 was associated with disease-free (p = 0.09) and overall survivals (p < 0.05) after lung resection. Such relationship was not observed among squamous cell carcinoma patients. Our findings indicate that Ets-1 expression is related to histopathological differentiation, morphogenesis, and tumor progression of lung adenocarcinomas. Ets-1 appears to be a useful predictor of poor prognosis after surgical resection in lung adenocarcinoma patients. Ets-1 expression could be used to evaluate the malignant behaviors of lung adenocarcinomas.
机译:原癌基因Ets-1是一种转录因子,已知可调节某些基质金属蛋白酶和纤溶酶原激活剂,它们与实体癌的恶性行为有关。我们假设Ets-1表达还与肺癌患者的肿瘤进展和更差的预后有关。为了阐明Ets-1原癌基因的作用,在156个经石蜡包埋的标本中,在手术切除的组织样本中确定了Ets-1在非小细胞肺癌中的表达。免疫组织化学染色显示Ets-1表达在156例癌症(82%)中的82例中:52例(69%)鳞状细胞癌中的36例,96例(43%)腺癌中的41例以及8例其他癌症中的5例(63%)。在腺癌中,与乳头状或肺泡型相比,腺泡型表达Ets-1的比例更高(p <0.05)。表达Ets-1的腺癌的比例随腺癌的组织学分化差而增加(p <0.05)。 Ets-1阳性腺癌的平均大小大于Ets-1阴性腺癌(p <0.01)。在腺癌患者中,Ets-1的表达与肺切除术后无病(p = 0.09)和总生存(p <0.05)有关。在鳞状细胞癌患者中未观察到这种关系。我们的发现表明,Ets-1表达与肺腺癌的组织病理学分化,形态发生和肿瘤进展有关。 Ets-1似乎是肺腺癌患者手术切除后不良预后的有用预测指标。 Ets-1表达可用于评估肺腺癌的恶性行为。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号